Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors.
Ashkar R, Feldman DR, Adra N, Zaid MA, Funt SA, Althouse SK, Perkins SM, Snow CI, Lazzara KM, Sego LM, Quinn DI, Hanna NH, Einhorn LH, Albany C.
Ashkar R, et al.
Invest New Drugs. 2021 Dec;39(6):1656-1663. doi: 10.1007/s10637-021-01134-1. Epub 2021 May 24.
Invest New Drugs. 2021.
PMID: 34031784
Free PMC article.
Clinical Trial.